On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 05/05/22
- Zillow drops 9% to $36.21 after Q2 revenue guidance misses estimates
- 05/05/22
- Zillow Group falls over 9% to $35.27 after Q1 results, below-consensus guidance
- 05/05/22
- Zillow Group board approves $1.0B buyback
- 02/10/22
- Zillow Group targeting annual revenue of $5B by 2025
- 01/07/22
- Zillow Group names Jenny Arden as Chief Design Officer
- 03/21/22
- Vistra names Jim Burke as next CEO, effective August 1
- 01/24/22
- Vistra expanding Moss Landing Energy Storage Facility
VRTX Vertex Pharmaceuticals - $253.65 /
-13.41 (-5.02%) - 05/05/22
- Vertex Pharmaceuticals still sees FY22 product revenues $8.4B-$8.6B
- 05/02/22
- Vertex Pharmaceuticals provides update on VX-880 trial
- 04/20/22
- Vertex says Health Canada grants marketing authorization for TRIKAFTA for 6-11
- 04/20/22
- Vertex Pharmaceuticals' Trikafta granted MAA in Canada for pediatric fibrosis
- $10.87 /
-3.425 (-23.96%) - 05/06/22
- Under Armour falls -22.0%
- 05/06/22
- Under Armour falls -24.7%
- 05/06/22
- Under Armour falls -20.7%
- 05/06/22
- Under Armour says growth will be tempered in 2023
- 05/06/22
- Under Armour falls -24.7%
- 05/06/22
- Under Armour falls -24.6%
- 05/06/22
- Under Armour falls -21.5%
- 05/06/22
- Elon Musk says hasn't had communication with Trump
- 05/06/22
- Vale confirms supply deal with Tesla for low-carbon nickel
- 05/03/22
- Musk says Twitter may include 'slight cost' for government users
- 05/03/22
- Elon Musk says Apple Store like having 30% internet tax
- 04/27/22
- Santander Consumer USA, Stellantis agree on U.S. contract extension
- 04/20/22
- EU passenger car registrations down 20.5% in March
- 04/19/22
- Stellantis suspends production in Russia
- 04/14/22
- Stellantis, Qualcomm collaborate to power vehicle platforms with Snapdragon
- 05/05/22
- Block jumps 9% to over $104 after reporting Q1 results
- 05/05/22
- Block sees Square GPV up 29% for April
- 05/03/22
- Rite Aid and Block unit Afterpay partner to offer BNPL on everyday items
- 04/29/22
- Jack Dorsey says Twitter needs transparency to 'earn trust'
- 05/05/22
- Virgin Galactic expects to launch commercial service in Q1 of 2023
- 05/05/22
- Virgin Galactic sees Q2 free cash flow of ($80M)-($90M)
- 02/22/22
- Virgin Galactic sees Q1 free cash flow of ($85M) to ($75M)
- 02/18/22
- Chamath Palihapitiya steps down from Virgin Galactic board
- 05/03/22
- Starbucks says suspending guidance for balance of year 'responsible'
- 05/03/22
- Starbucks interim CEO Schultz to remain on board after CEO transition
- 05/03/22
- Starbucks jumps 5% to $78.03 after Q2 results
- 05/03/22
- Starbucks says union contracts would be 'inferior' to what the company offers
RADI Radius Global Infrastructure - 05/06/22
- Radius Global up 15% after Bloomberg says company exploring options
- 04/14/22
- Peloton Interactive trading resumes
- 04/14/22
- Peloton jumped 1% to $25.28 before halt after Bloomberg report
- 04/14/22
- Peloton Interactive trading halted, volatility trading pause
- 03/10/22
- Peloton names Andrew Rendich as Chief Supply Chain Officer, effective March 16
- $65.56 /
-12.305 (-15.80%) - 04/14/22
- Cloudflare president Zatlyn sells $1.48M in company shares
- 03/22/22
- Cloudflare CEO says Okta may have data issue, resetting credentials
- 03/17/22
- Cloudflare, Crowdstrike expand partnership
- 02/23/22
- Cloudflare to acquire Area 1 Security for $162M
MLCO Melco Resorts & Entertainment - 05/02/22
- Macau reports April casino revenue down 68.1% to 2.68B patacas
- 04/13/22
- Melco Resorts & Entertainment enters partnership with Cogniac
- 04/12/22
- Microvast, China Automotive among new additions to SEC HFCAA provisional list
- 04/01/22
- Macau reports March casino revenue down 55.8% to 3.67B patacas
- 05/05/22
- FDA limits authorized use of J&J's COVID vaccine
- 05/02/22
- FDA announces tentative advisory committee meetings on COVID-19 vaccines
- 05/02/22
- Roivant Sciences announces collaborations in targeted protein degradation
- 04/19/22
- Johnson & Johnson announces $77M opioid settlement with Alabama
- 05/06/22
- Goodyear Tire reports Q1 tire unit volumes 45M, up 29% y/y
- 04/07/22
- Goodyear Tire to co-develop domestic source of natural rubber
- 02/27/22
- Fly Intel: Top five weekend stock stories
- 02/11/22
- Goodyear Tire sees 2022 cash flow 'around breakeven,' says CFO
- 05/05/22
- GoPro sees FY22 gross margin 40%-43%
- 03/31/22
- GoPro launches HERO10 Black Creator Edition
- 02/03/22
- GoPro sees slight unit growth, increasing ASPs in FY22
- 05/06/22
- FuboTV falls -17.9%
- 05/06/22
- FuboTV falls -24.8%
- 05/05/22
- FuboTV reports Q1 North America subscribers 1.06M, up 81% from last year
- 04/19/22
- Roku drops 6% to $109.96 after Netflix losses subscribers in Q1
- $21.25 /
+4.545 (+27.22%) - 05/05/22
- Funko up 26% after Q1 earnings beat, $263M investment from eBay-led consortium
- 05/05/22
- Funko trading resumes
- 05/05/22
- Chernin Group-led consortium to make $263M strategic investment in Funko
- 05/05/22
- eBay part of consortium acquiring 12.5M Funko shares
- 05/02/22
- Endo subsidiary acquires six product candidates from Nevakar for $35M
- 05/02/22
- Nevakar Injectables sells six development stage product candidates to Endo
- 04/28/22
- Nevakar receives FDA approval of ready-to-use Ephedrine Sulfate Injection
- 04/20/22
- Endo provides update on recusal of liability case judge
- 05/05/22
- Chernin Group-led consortium to make $263M strategic investment in Funko
- 05/04/22
- eBay reports Q1 GMV $19.4B, down 20% on an as reported basis
- 05/05/22
- DraftKings completes acquisition of Golden Nugget Online Gaming
- 05/03/22
- DraftKings announces Metabilia to become latest NFT supplier on its marketplace
- 05/02/22
- Cathie Wood's ARK Investment bought 189K shares of DraftKings today
- 04/28/22
- Nevada reports March statewide gaming win up 26.8% to $1.36B
- 05/03/22
- Samsung selected for deployment of 5G solutions across Dish network
- 05/02/22
- Ceragon to provide 5G wireless transport solutions to Dish Wireless
- 02/04/22
- Dish, Tegna reach new carriage agreement
- 01/18/22
- Dish Wireless, WCI Technologies announce partnership
- $266.82 /
+14.69 (+5.83%) - 05/02/22
- Bioventus agrees to nationwide contract with Cigna for DUROLANE, GELSYN-3
- 03/08/22
- Kala Pharmaceuticals announces EYSUVIS now covered by UnitedHealthcare, Cigna
- 02/28/22
- Cigna to increase share repurchase authorization by $6B
- 02/18/22
- Cigna CHRO John Murabito to retire, Cynthia Ryan to succeed
- 04/13/22
- ChemoCentryx reports PK, PD data from ongoing Phase I study of CCX559
- 01/19/22
- ChemoCentryx announces EU approval of TAVNEOS
- 11/12/21
- ChemoCentryx receives positive recommendation for use of TAVNEOS by EMA
- 05/06/22
- Bausch + Lomb launches as publicly traded company
- 05/06/22
- Bausch Health down 2% after opening of Bausch + Lomb IPO
- 04/28/22
- Bausch Health announces arrangement agreement with Bausch + Lomb
- $120.88 /
-31.47 (-20.66%) - 05/06/22
- Bill.com falls -26.9%
- 03/17/22
- Bill.com appoints Rinki Sethi to VP and Chief Information Security Officer
- 02/04/22
- Bill.com rises 31.8%
- 02/04/22
- Bill.com rises 25.3%
- 05/06/22
- Bausch Health appoints Richard Mulligan to board of directors
- 05/06/22
- Bausch Health appoints Thomas Appio as CEO
- 05/03/22
- Bausch Health announces data from NOV03 trial
- $2,294.47 /
-31.49 (-1.35%) - 05/05/22
- Fluence Energy partners with Amazon.com for cloud computing services
- 05/03/22
- Seritage Growth Properties signs lease with Amazon in California
- 05/03/22
- Amazon to create 2,500 corporate and tech Jobs in California with expansion
- 05/02/22
- Amazon's PillPack settles insulin overbilling claims for $5.79M
- 05/03/22
- Amarin announces publication of new REDUCE-IT data analysis
- 04/26/22
- Amarin partner HLS Therapeutics completes reimbursement negotiations with pCPA
- 04/01/22
- Amarin announces in vitro results on EPA in combination with prescribed statins
- 03/28/22
- Amarin r3eeives reimbursement for VAZKEPA in Sweden
- 05/06/22 Truist
- Block price target lowered to $165 from $220 at Truist
- 05/06/22 Cowen
- Block price target lowered to $148 from $188 at Cowen
- 05/06/22 MoffettNathanson
- Block price target lowered to $170 from $200 at MoffettNathanson
- 05/06/22 BTIG
- Block price target lowered to $175 from $230 at BTIG
- 05/06/22 Benchmark
- Zillow Group price target lowered to $65 from $115 at Benchmark
- 05/06/22 Truist
- Zillow Group price target lowered to $41 from $58 at Truist
- 05/06/22 Piper Sandler
- Zillow Group price target lowered to $39 from $57 at Piper Sandler
- 04/26/22 RBC Capital
- Zillow Group price target lowered to $65 from $70 at RBC Capital
- 03/30/22 Goldman Sachs
- Zillow Group initiated with a Neutral at Goldman Sachs
- 03/17/22 Piper Sandler
- Zillow Group price target lowered to $57 from $64 at Piper Sandler
- $10.87 /
-3.425 (-23.96%) - 05/06/22 Stifel
- Under Armour price target lowered to $13 from $18 at Stifel
- 04/26/22 OTR Global
- Under Armour view downgraded to Mixed from Positive at OTR Global
- 04/25/22 Deutsche Bank
- Skechers price target lowered to $61 from $62 at Deutsche Bank
- 04/01/22 Barclays
- Under Armour price target lowered to $22 from $24 at Barclays
- 03/09/22 JPMorgan
- Under Armour price target lowered to $23 from $28 at JPMorgan
- 04/29/22 Chardan
- Emergent BioSolutions price target lowered to $65 from $75 at Chardan
- 04/20/22 Credit Suisse
- Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
- 04/20/22 Citi
- Johnson & Johnson price target raised to $210 from $203 at Citi
- 04/19/22 Stifel
- J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
- 02/01/22 RBC Capital
- Bausch Health price target lowered to $34 from $40 at RBC Capital
- 11/03/21 JPMorgan
- Bausch Health earnings selloff a buying opportunity, says JPMorgan
- 09/21/21 JPMorgan
- Bausch has 50% upside based on sum-of-the-parts, says JPMorgan
- 08/04/21 JPMorgan
- Bausch Health selloff on Solta IPO plans overdone, says JPMorgan
- 05/06/22 Needham
- FuboTV price target lowered to $5 from $15 at Needham
- 05/06/22 Evercore ISI
- FuboTV price target lowered to $7 from $20 at Evercore ISI
- 05/06/22 JPMorgan
- FuboTV downgraded to Underweight from Neutral at JPMorgan
- 05/06/22 Roth Capital
- FuboTV downgraded to Neutral on slowing growth at Roth Capital
VRTX Vertex Pharmaceuticals - $253.65 /
-13.41 (-5.02%) - 05/06/22 Wells Fargo
- Vertex Pharmaceuticals price target raised to $305 from $300 at Wells Fargo
- 05/06/22 Baird
- Vertex Pharmaceuticals downgraded to Neutral at Baird after 21% advance
- 05/06/22 Baird
- Vertex Pharmaceuticals downgraded to Neutral from Outperform at Baird
- 05/06/22 Piper Sandler
- Vertex Pharmaceuticals price target lowered to $242 from $249 at Piper Sandler
MLCO Melco Resorts & Entertainment - 05/06/22 CLSA
- Melco Resorts & Entertainment upgraded to Buy from Outperform at CLSA
- 04/12/22 Citi
- Citi opens '30-day positive Catalyst Watches' on Melco, Galaxy
- 01/18/22 Citi
- Melco Resorts & Entertainment price target raised to $15 from $13.50 at Citi
- 01/10/22 Citi
- Melco Resorts price target lowered to $13.50 from $14.50 at Citi
- 05/06/22 JPMorgan
- JPMorgan downgrades Amarin to sell on headwinds in U.S., Europe
- 05/06/22 JPMorgan
- Amarin downgraded to Underweight from Neutral at JPMorgan
- 05/05/22 H.C. Wainwright
- Amarin downgraded to Neutral from Buy at H.C. Wainwright
- 05/05/22 SVB Leerink
- Amarin downgraded to Market Perform from Outperform at SVB Leerink
- 05/06/22 Canaccord
- Virgin Galactic downgraded to Hold at Canaccord after commercial launch delay
- 05/06/22 Canaccord
- Virgin Galactic downgraded to Hold from Buy at Canaccord
- 02/24/22 Cowen
- Virgin Galactic price target lowered to $15 from $25 at Cowen
- 02/24/22 Susquehanna
- Virgin Galactic price target lowered to $9.00 from $22 at Susquehanna
- 04/19/22 Citi
- Peloton assumed with Buy from Neutral at Citi
- 04/08/22 Morgan Stanley
- Peloton may top 3M Connected Fitness subscribers in Q3, says Morgan Stanley
- 03/31/22 Evercore ISI
- Peloton shares may stay range-bound in near-to-mid-term, says Evercore ISI
- 03/14/22 Bernstein
- Peloton initiated with an Outperform at Bernstein
- 04/27/22 Wedbush
- Twitter transaction 'was never ideal' for Tesla investors, says Wedbush
- 04/26/22 Wedbush
- 'Soap opera' now ends with Musk owning Twitter, says Wedbush
- 04/25/22 Gordon Haskett
- Twitter bid more attractive after market selloff, says Gordon Haskett
- 04/25/22 Wedbush
- Twitter bid unlikely to result in major sale of Musk's Tesla stock, says Wedbush
- $2,294.47 /
-31.49 (-1.35%) - 05/02/22 Piper Sandler
- Piper Sandler favors Rivian for exposure to commercial vans
- 05/02/22 Wedbush
- Amazon.com removed from Best Ideas List at Wedbush
- 05/02/22 KeyBanc
- Shopify price target lowered to $650 from $1,000 at KeyBanc
- 05/02/22 Citi
- Amazon overcapacity already previewed in UPS results, says Citi
RADI Radius Global Infrastructure - 11/12/21
- Fly Intel: Top five analyst upgrades
- 11/12/21 Raymond James
- Raymond James upgrades Radius Global to Strong Buy on 'significant upside'
- 11/12/21 Raymond James
- Radius Global upgraded to Strong Buy from Outperform at Raymond James
- 05/04/22 MKM Partners
- Starbucks price target lowered to $98 from $105 at MKM Partners
- 05/04/22 Morgan Stanley
- Starbucks price target lowered to $87 from $94 at Morgan Stanley
- 05/04/22 Cowen
- Starbucks price target lowered to $94 from $115 at Cowen
- 05/04/22 BMO Capital
- Starbucks price target lowered to $105 from $115 at BMO Capital
- $21.25 /
+4.545 (+27.22%) - 03/07/22 BMO Capital
- Funko price target raised to $21 from $18 at BMO Capital
- 03/04/22 DA Davidson
- Funko price target raised to $46 from $34 at DA Davidson
- 08/31/21
- Fly Intel: Top five analyst upgrades
- 08/31/21 Jefferies
- Jefferies upgrades Funko to Buy on confidence in 10%-plus growth
- 05/06/22 Wells Fargo
- eBay price target lowered to $58 from $65 at Wells Fargo
- 05/06/22 Mizuho
- eBay price target lowered to $50 from $60 at Mizuho
- 05/05/22 Baird
- eBay price target lowered to $65 from $80 at Baird
- 05/05/22 Stifel
- eBay price target lowered to $62 from $70 at Stifel
- 03/02/22 Raymond James
- ChemoCentryx could beat consensus 'handily' in Q2, says Raymond James
- 03/02/22 Stifel
- ChemoCentryx's Q4 was positive-launch quarter, says Stifel
- 11/15/21 Raymond James
- InflaRx's ANCA vasculitis data 'solid,' says Raymond James
- 11/10/21 Raymond James
- ChemoCentryx price target raised to $110 from $107 at Raymond James
- 10/13/21 BMO Capital
- Vistra price target raised to $27 from $25 at BMO Capital
- 09/30/21 BofA
- Vistra added to 'US 1 list' at BofA
- 09/29/21 BofA
- Vistra added to US 1 List at BofA
- 07/22/21 Guggenheim
- Guggenheim says 'time is right' to upgrade Vistra to Buy
- 05/06/22 DZ Bank
- Stellantis upgraded to Buy from Hold at DZ Bank
- 04/26/22 BofA
- Stellantis downgraded to Neutral from Buy at BofA
- 03/23/22 RBC Capital
- RBC cut 2022, 2023 auto forecast on lingering supply chain issues
- 03/15/22 Jefferies
- Stellantis price target lowered to EUR 20 from EUR 25 at Jefferies
- 05/06/22 Citi
- GoPro price target lowered to $8 from $9 at Citi
- 03/14/22 Jefferies
- Jefferies 'pleased' to see GoPro taking 'more aggressive competitive posture'
- 02/28/22 Jefferies
- Jefferies starts GoPro at Buy after 'impressive strategic realignment'
- 02/28/22 Jefferies
- GoPro initiated with a Buy at Jefferies
- 05/06/22 Piper Sandler
- Piper downgrades Endo to sell, says 'going from bad to worse'
- 05/06/22 Piper Sandler
- Endo downgraded to Underweight from Neutral at Piper Sandler
- 03/09/22 Citi
- Endo price target lowered to $6 from $11 at Citi
- 03/03/22 BMO Capital
- Endo price target lowered to $4 from $8 at BMO Capital
- $120.88 /
-31.47 (-20.66%) - 05/06/22 Needham
- Bill.com price target lowered to $200 from $370 at Needham
- 05/06/22 BTIG
- Bill.com price target lowered to $300 from $375 at BTIG
- 05/06/22 Canaccord
- Bill.com price target lowered to $250 from $366 at Canaccord
- 05/06/22 Oppenheimer
- Bill.com price target lowered to $190 from $285 at Oppenheimer
- 05/04/22 Cowen
- DraftKings price target lowered to $50 from $60 at Cowen
- 03/17/22 UBS
- Genius Sports price target lowered to $5 from $9 at UBS
- 03/17/22 UBS
- DraftKings price target lowered to $18 from $44 at UBS
- 03/07/22 Argus
- DraftKings cut to Hold at Argus on growing Wynn and MGM competition
- $266.82 /
+14.69 (+5.83%) - 04/07/22 Truist
- Cigna price target raised to $290 from $275 at Truist
- 03/02/22 Mizuho
- Cigna price target raised to $266 from $245 at Mizuho
- 02/07/22 RBC Capital
- Cigna downgraded to Sector Perform from Outperform at RBC Capital
- 02/07/22 Barclays
- Convey Health price target lowered to $12 from $16 at Barclays
- 03/21/22 Citi
- Dish price target lowered to $46 from $52 at Citi
- 03/08/22 UBS
- Dish upgraded to Buy from Neutral at UBS
- 02/25/22 Truist
- Dish price target lowered to $32 from $40 at Truist
- 02/25/22 Deutsche Bank
- Dish shares have bottomed, says Deutsche Bank
- $65.56 /
-12.305 (-15.80%) - 05/06/22 Truist
- Cloudflare price target lowered to $140 from $180 at Truist
- 05/06/22 Mizuho
- Cloudflare price target lowered to $90 from $135 at Mizuho
- 05/06/22 Citi
- Cloudflare price target lowered to $95 from $120 at Citi
- 05/02/22 Cowen
- Cloudflare price target lowered to $200 from $250 at Cowen
- 04/21/22 Deutsche Bank
- Goodyear Tire price target lowered to $19 from $30 at Deutsche Bank
- 04/11/22 Exane BNP Paribas
- Goodyear Tire initiated with a Neutral at Exane BNP Paribas
- 02/22/22 Jefferies
- Goodyear Tire downgraded to Hold from Buy at Jefferies
- 02/14/22 Nomura
- Goodyear Tire upgraded to Neutral at Nomura after selloff
- 05/05/22
- Zillow Group sees Q2 revenue $903M-$1.03B, consensus $1.81B
- 05/05/22
- Zillow reports Q1 consolidated Adjusted EBITDA of $220M
- 02/10/22
- Notable companies reporting after market close
- 02/10/22
- Zillow reports Q4 consolidated Adjusted EBITDA ($0.4M)
- 05/06/22
- Vistra reports Q1 revenue $3.13B, consensus $3.21B
VRTX Vertex Pharmaceuticals - $253.65 /
-13.41 (-5.02%) - 05/05/22
- Vertex Pharmaceuticals reports Q1 adjusted EPS $3.52, consensus $3.49
- 01/26/22
- Vertex Pharmaceuticals reports Q4 EPS $3.37, consensus $3.29
- 01/26/22
- Notable companies reporting after market close
- $10.87 /
-3.425 (-23.96%) - 05/06/22
- Under Armour sees Q1 EPS 2c-3c, consensus 12c
- 05/06/22
- Under Armour sees FY23 adjusted EPS 63c-68c, consensus 83c
- 05/06/22
- Under Armour reports transition quarter adjusted EPS 1c, consensus 6c
- 05/05/22
- Notable companies reporting before tomorrow's open
- 04/20/22
- Tesla reports Q1 EPS $3.22, consensus $2.26
- 04/20/22
- Notable companies reporting after market close
- 01/26/22
- Tesla reports Q4 non-GAAP EPS $2.54, consensus $2.26
- 05/05/22
- Stellantis reports Q1 revenue EUR 41.5B vs. EUR 37B last year
- 02/23/22
- Stellantis reports FY21 IFRS net revenue EUR 149.42B vs. EUR 47.66B last year
- 05/05/22
- Block reports Q1 adjusted EPS 18c, consensus 21c
- 05/05/22
- Notable companies reporting after market close
- 02/24/22
- Block reports Q4 adjusted EPS 27c, consensus 22c
- 02/24/22
- Notable companies reporting after market close
- 05/05/22
- Virgin Galactic reports Q1 EPS (36c), consensus (32c)
- 02/22/22
- Virgin Galactic reports Q4 EPS (31c), consensus (34c)
- 02/22/22
- Notable companies reporting after market close
- 05/03/22
- Starbucks suspends guidance for Q3 and Q4
- 05/03/22
- Starbucks reports Q2 adjusted EPS 59c, consensus 59c
- 05/03/22
- Notable companies reporting after market close
- 02/01/22
- Starbucks cuts FY22 adjusted EPS growth view to 8%-10% from at least 10%
RADI Radius Global Infrastructure - 02/28/22
- Radius Global Infrastructure reports Q4 revenue $29M, consensus $29.52M
- 11/10/21
- Radius Global Infrastructure reports Q3 EPS (11c), two estimates (31c)
- 02/08/22
- Peloton sees FY22 revenue $3.7B-$3.8B, consensus $4.26B
- 02/08/22
- Peloton sees Q3 revenue $950M-$1B, consensus $1.26B
- 02/08/22
- Peloton reports Q2 EPS ($1.39), consensus ($1.20)
- 01/20/22
- Peloton sees Q2 revenue $1.14B, consensus $1.15B
- $65.56 /
-12.305 (-15.80%) - 05/05/22
- Cloudflare backs FY22 adjusted EPS view 3c-4c, consensus 3c
- 05/05/22
- Cloudflare sees Q2 adjusted EPS (1c)-0c, consensus 0c
- 05/05/22
- Cloudflare reports Q1 adjusted EPS 1c, consensus 0c
MLCO Melco Resorts & Entertainment - 05/05/22
- Melco Resorts & Entertainment reports Q1 EPS 38.8c vs 48.8c last year
- 03/01/22
- Melco Resorts & Entertainment reports Q4 EPS (11.2c) vs. (14c) last year
- 11/09/21
- Melco Resorts & Entertainment reports Q3 EPS (48.7c) vs (69.6c) last year
- 04/19/22
- Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60
- 04/19/22
- Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61
- 04/18/22
- Notable companies reporting before tomorrow's open
- 05/06/22
- Goodyear Tire reports Q1 adjusted EPS 37c, consensus 21c
- 02/11/22
- Goodyear Tire reports Q4 adjusted EPS 57c, consensus 32c
- 05/05/22
- GoPro sees Q2 EPS 6c, plus or minus 2c, consensus 15c
- 05/05/22
- GoPro reports Q1 adjusted EPS 9c, consensus 6c
- 02/03/22
- GoPro sees Q1 revenue $210M-$220M, consensus $235.5M
- 05/05/22
- FuboTV reports Q1 EPS (69c), consensus (65c)
- 02/23/22
- FuboTV reports Q4 EPS (57c), consensus (67c)
- 02/23/22
- Notable companies reporting after market close
- $21.25 /
+4.545 (+27.22%) - 05/05/22
- Funko narrows FY22 EPS view to $1.80-$1.90 from $1.75-$1.91
- 05/05/22
- Funko reports Q1 adjusted EPS 34c, consensus 22c
- 03/03/22
- Funko sees Q1 revenue growth mid-40% range, consensus $205.51M
- 03/03/22
- Funko sees FY22 adjusted EPS $1.75-$1.91, consensus $1.43
- 05/05/22
- Endo sees Q2 adjusted cont ops EPS (17c)-(15c), consensus 48c
- 05/05/22
- Endo reports Q1 adjusted EPS 66c, consensus 44c
- 02/28/22
- Endo sees Q1 EPS 35c-45c, consensus 48c
- 02/28/22
- Endo reports Q4 EPS 84c, consensus 67c
- 05/04/22
- eBay cuts FY22 adj. EPS view to $3.90-$4.10 from $4.20-$4.40
- 05/04/22
- eBay sees Q2 adjusted EPS 87c-91c, consensus $1.01
- 05/04/22
- eBay reports Q1 adjusted EPS $1.05, consensus $1.03
- 05/04/22
- Notable companies reporting after market close
- 05/06/22
- DraftKings raises 2022 revenue view $1.925B-$2.025B from $1.85B-$2B
- 05/06/22
- DraftKings reports Q1 revenue $417M, consensus $412.01M
- 02/18/22
- DraftKings raises 2022 revenue view $1.85B-$2B from $1.7B-$1.9B, consensus $1.9B
- 02/18/22
- DraftKings reports Q4 revenue $473M, consensus $445.3M
- 05/06/22
- Dish reports Q1 EPS 68c, consensus 75c
- 02/24/22
- Dish reports Q4 EPS 87c, consensus 87c
- $266.82 /
+14.69 (+5.83%) - 05/06/22
- Cigna raises FY22 adjusted EPS view to at least $22.60 from at least $22.40
- 05/06/22
- Cigna reports Q1 adjusted EPS $6.01, consensus $5.18
- 05/05/22
- ChemoCentryx reports Q1 EPS (55c), consensus (30c)
- 03/01/22
- ChemoCentryx reports Q4 EPS (58c), consensus (58c)
- 11/09/21
- ChemoCentryx reports Q3 EPS (32c), consensus (45c)
- $120.88 /
-31.47 (-20.66%) - 05/05/22
- Bill.com sees FY22 EPS (35c)-(34c), consensus (46c)
- 05/05/22
- Bill.com sees Q4 EPS (14c)-(13c), consensus (15c)
- 05/05/22
- Bill.com reports Q3 EPS (8c), consensus (16c)
- 02/23/22
- Bausch Health sees FY22 revenue $8.4B-8.6B, consensus $8.74B
- 02/23/22
- Bausch Health reports Q4 GAAP EPS 19c, consensus $1.11
- $2,294.47 /
-31.49 (-1.35%) - 05/05/22
- AES Corp.to provide 450 MW of renewable energy to Amazon
- 04/28/22
- Amazon sees Q2 revenue $116B-$121B, consensus $125.55B
- 04/28/22
- Amazon reports Q1 EPS ($7.56) with Rivian expense, consensus $8.36
- 04/28/22
- Notable companies reporting after market close
- 05/04/22
- Amarin reports Q1 adjusted EPS (6c), consensus (2c)
- 03/01/22
- Amarin reports Q4 adjusted EPS 6c, consensus (2c)
- 01/10/22
- Amarin unable to provide 2022 revenue guidance
- 01/10/22
- Amarin reports 2021 revenue $580M, consensus $596.02M
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 05/05/22
- Zillow drops 9% to $36.21 after Q2 revenue guidance misses estimates
- 05/05/22
- Zillow Group falls over 9% to $35.27 after Q1 results, below-consensus guidance
- 05/05/22
- Zillow Group board approves $1.0B buyback
- 02/10/22
- Zillow Group targeting annual revenue of $5B by 2025
- 01/07/22
- Zillow Group names Jenny Arden as Chief Design Officer
- 03/21/22
- Vistra names Jim Burke as next CEO, effective August 1
- 01/24/22
- Vistra expanding Moss Landing Energy Storage Facility
VRTX Vertex Pharmaceuticals - $254.63 /
-12.43 (-4.65%) - 05/05/22
- Vertex Pharmaceuticals still sees FY22 product revenues $8.4B-$8.6B
- 05/02/22
- Vertex Pharmaceuticals provides update on VX-880 trial
- 04/20/22
- Vertex says Health Canada grants marketing authorization for TRIKAFTA for 6-11
- 04/20/22
- Vertex Pharmaceuticals' Trikafta granted MAA in Canada for pediatric fibrosis
- $11.26 /
-3.035 (-21.23%) - 05/06/22
- Under Armour falls -22.0%
- 05/06/22
- Under Armour falls -24.7%
- 05/06/22
- Under Armour falls -20.7%
- $10.02 /
-3.245 (-24.46%) - 05/06/22
- Under Armour falls -24.7%
- 05/06/22
- Under Armour falls -24.6%
- 05/06/22
- Under Armour falls -21.5%
- 05/06/22
- Under Armour says growth will be tempered in 2023
- 05/06/22
- Elon Musk says hasn't had communication with Trump
- 05/06/22
- Vale confirms supply deal with Tesla for low-carbon nickel
- 05/03/22
- Musk says Twitter may include 'slight cost' for government users
- 05/03/22
- Elon Musk says Apple Store like having 30% internet tax
- 04/27/22
- Santander Consumer USA, Stellantis agree on U.S. contract extension
- 04/20/22
- EU passenger car registrations down 20.5% in March
- 04/19/22
- Stellantis suspends production in Russia
- 04/14/22
- Stellantis, Qualcomm collaborate to power vehicle platforms with Snapdragon
- 05/05/22
- Block jumps 9% to over $104 after reporting Q1 results
- 05/05/22
- Block sees Square GPV up 29% for April
- 05/03/22
- Rite Aid and Block unit Afterpay partner to offer BNPL on everyday items
- 04/29/22
- Jack Dorsey says Twitter needs transparency to 'earn trust'
- 05/05/22
- Virgin Galactic expects to launch commercial service in Q1 of 2023
- 05/05/22
- Virgin Galactic sees Q2 free cash flow of ($80M)-($90M)
- 02/22/22
- Virgin Galactic sees Q1 free cash flow of ($85M) to ($75M)
- 02/18/22
- Chamath Palihapitiya steps down from Virgin Galactic board
- 05/05/22
- Microsoft says 'Fortnite' to be available on Xbox Cloud Gaming
- 05/04/22
- U.S. video game spending falls 8% y/y in Q1, says NPD
- 04/25/22
- Bandai Namco's 'Elden Ring' repeats as best-selling U.S. game in March, says NPD
- 04/25/22
- March 2022 video game spending fell 15% y/y to $4.9B, says NPD
- 04/14/22
- Peloton Interactive trading resumes
- 04/14/22
- Peloton jumped 1% to $25.28 before halt after Bloomberg report
- 04/14/22
- Peloton Interactive trading halted, volatility trading pause
- 03/10/22
- Peloton names Andrew Rendich as Chief Supply Chain Officer, effective March 16
- $67.14 /
-10.72 (-13.77%) - 04/14/22
- Cloudflare president Zatlyn sells $1.48M in company shares
- 03/22/22
- Cloudflare CEO says Okta may have data issue, resetting credentials
- 03/17/22
- Cloudflare, Crowdstrike expand partnership
- 02/23/22
- Cloudflare to acquire Area 1 Security for $162M
MLCO Melco Resorts & Entertainment - 05/02/22
- Macau reports April casino revenue down 68.1% to 2.68B patacas
- 04/13/22
- Melco Resorts & Entertainment enters partnership with Cogniac
- 04/12/22
- Microvast, China Automotive among new additions to SEC HFCAA provisional list
- 04/01/22
- Macau reports March casino revenue down 55.8% to 3.67B patacas
- 05/05/22
- FDA limits authorized use of J&J's COVID vaccine
- 05/02/22
- FDA announces tentative advisory committee meetings on COVID-19 vaccines
- 05/02/22
- Roivant Sciences announces collaborations in targeted protein degradation
- 04/19/22
- Johnson & Johnson announces $77M opioid settlement with Alabama
- 04/11/22
- Cohen & Steers Capital issues statement on Southwest Gas Holdings
- 03/23/22
- Icahn Enterprises announces amendment to Southwest Gas Tender Offer
- 03/14/22
- Icahn Enterprises raises tender offer price for Southwest Gas to $82.50
- 03/07/22
- Delek US to purchase $64M of its shares from Icahn Group
- 05/06/22
- Goodyear Tire reports Q1 tire unit volumes 45M, up 29% y/y
- 04/07/22
- Goodyear Tire to co-develop domestic source of natural rubber
- 02/27/22
- Fly Intel: Top five weekend stock stories
- 02/11/22
- Goodyear Tire sees 2022 cash flow 'around breakeven,' says CFO
- 05/05/22
- GoPro sees FY22 gross margin 40%-43%
- 03/31/22
- GoPro launches HERO10 Black Creator Edition
- 02/03/22
- GoPro sees slight unit growth, increasing ASPs in FY22
- 05/06/22
- FuboTV falls -17.9%
- 05/06/22
- FuboTV falls -24.8%
- 05/05/22
- FuboTV reports Q1 North America subscribers 1.06M, up 81% from last year
- 04/19/22
- Roku drops 6% to $109.96 after Netflix losses subscribers in Q1
- 05/05/22
- Funko up 26% after Q1 earnings beat, $263M investment from eBay-led consortium
- 05/05/22
- Funko trading resumes
- 05/05/22
- Chernin Group-led consortium to make $263M strategic investment in Funko
- 05/05/22
- eBay part of consortium acquiring 12.5M Funko shares
- 05/05/22
- mPhase Technologies announces first auto dealer EV charging contract
- 05/05/22
- Blink Charging appoints Stelea VP of Investor Relations
- 05/04/22
- Ford reports April U.S. electric vehicle sales of 16,779 vehicles, up 50%
- 05/04/22
- Ford reports April U.S. vehicle sales of 176,965 vehicles, down 10.5%
- 05/02/22
- Endo subsidiary acquires six product candidates from Nevakar for $35M
- 05/02/22
- Nevakar Injectables sells six development stage product candidates to Endo
- 04/28/22
- Nevakar receives FDA approval of ready-to-use Ephedrine Sulfate Injection
- 04/20/22
- Endo provides update on recusal of liability case judge
- 05/05/22
- Chernin Group-led consortium to make $263M strategic investment in Funko
- 05/04/22
- eBay reports Q1 GMV $19.4B, down 20% on an as reported basis
- 05/05/22
- DraftKings completes acquisition of Golden Nugget Online Gaming
- 05/03/22
- DraftKings announces Metabilia to become latest NFT supplier on its marketplace
- 05/02/22
- Cathie Wood's ARK Investment bought 189K shares of DraftKings today
- 04/28/22
- Nevada reports March statewide gaming win up 26.8% to $1.36B
- $24.00 /
-3.485 (-12.68%) - 05/03/22
- Samsung selected for deployment of 5G solutions across Dish network
- 05/02/22
- Ceragon to provide 5G wireless transport solutions to Dish Wireless
- 02/04/22
- Dish, Tegna reach new carriage agreement
- 01/18/22
- Dish Wireless, WCI Technologies announce partnership
- $262.98 /
+10.85 (+4.30%) - 05/02/22
- Bioventus agrees to nationwide contract with Cigna for DUROLANE, GELSYN-3
- 03/08/22
- Kala Pharmaceuticals announces EYSUVIS now covered by UnitedHealthcare, Cigna
- 02/28/22
- Cigna to increase share repurchase authorization by $6B
- 02/18/22
- Cigna CHRO John Murabito to retire, Cynthia Ryan to succeed
- 04/13/22
- ChemoCentryx reports PK, PD data from ongoing Phase I study of CCX559
- 01/19/22
- ChemoCentryx announces EU approval of TAVNEOS
- 11/12/21
- ChemoCentryx receives positive recommendation for use of TAVNEOS by EMA
- $127.70 /
-24.65 (-16.18%) - 05/06/22
- Bill.com falls -26.9%
- 03/17/22
- Bill.com appoints Rinki Sethi to VP and Chief Information Security Officer
- 02/04/22
- Bill.com rises 31.8%
- 02/04/22
- Bill.com rises 25.3%
- $2,324.78 /
-1.18 (-0.05%) - 05/05/22
- Fluence Energy partners with Amazon.com for cloud computing services
- 05/03/22
- Seritage Growth Properties signs lease with Amazon in California
- 05/03/22
- Amazon to create 2,500 corporate and tech Jobs in California with expansion
- 05/02/22
- Amazon's PillPack settles insulin overbilling claims for $5.79M
- 05/03/22
- Amarin announces publication of new REDUCE-IT data analysis
- 04/26/22
- Amarin partner HLS Therapeutics completes reimbursement negotiations with pCPA
- 04/01/22
- Amarin announces in vitro results on EPA in combination with prescribed statins
- 03/28/22
- Amarin r3eeives reimbursement for VAZKEPA in Sweden
- 05/06/22 Truist
- Block price target lowered to $165 from $220 at Truist
- 05/06/22 Cowen
- Block price target lowered to $148 from $188 at Cowen
- 05/06/22 MoffettNathanson
- Block price target lowered to $170 from $200 at MoffettNathanson
- 05/06/22 BTIG
- Block price target lowered to $175 from $230 at BTIG
- 04/29/22 Chardan
- Emergent BioSolutions price target lowered to $65 from $75 at Chardan
- 04/20/22 Credit Suisse
- Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
- 04/20/22 Citi
- Johnson & Johnson price target raised to $210 from $203 at Citi
- 04/19/22 Stifel
- J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
- 05/06/22 Benchmark
- Zillow Group price target lowered to $65 from $115 at Benchmark
- 05/06/22 Truist
- Zillow Group price target lowered to $41 from $58 at Truist
- 05/06/22 Piper Sandler
- Zillow Group price target lowered to $39 from $57 at Piper Sandler
- 04/26/22 RBC Capital
- Zillow Group price target lowered to $65 from $70 at RBC Capital
- 03/30/22 Goldman Sachs
- Zillow Group initiated with a Neutral at Goldman Sachs
- 03/17/22 Piper Sandler
- Zillow Group price target lowered to $57 from $64 at Piper Sandler
- $10.02 /
-3.245 (-24.46%) - 04/26/22 OTR Global
- Under Armour view downgraded to Mixed from Positive at OTR Global
- 04/01/22 Barclays
- Under Armour price target lowered to $22 from $24 at Barclays
- 03/09/22 JPMorgan
- Under Armour price target lowered to $23 from $28 at JPMorgan
- 03/01/22 Cowen
- Cowen likes Under Armour stepping up buybacks, trims target to $27
- $11.26 /
-3.035 (-21.23%) - 04/25/22 Deutsche Bank
- Skechers price target lowered to $61 from $62 at Deutsche Bank
- 05/04/22 Cowen
- DraftKings price target lowered to $50 from $60 at Cowen
- 03/17/22 UBS
- Genius Sports price target lowered to $5 from $9 at UBS
- 03/17/22 UBS
- DraftKings price target lowered to $18 from $44 at UBS
- 03/07/22 Argus
- DraftKings cut to Hold at Argus on growing Wynn and MGM competition
- 04/19/22 Citi
- Peloton assumed with Buy from Neutral at Citi
- 04/08/22 Morgan Stanley
- Peloton may top 3M Connected Fitness subscribers in Q3, says Morgan Stanley
- 03/31/22 Evercore ISI
- Peloton shares may stay range-bound in near-to-mid-term, says Evercore ISI
- 03/14/22 Bernstein
- Peloton initiated with an Outperform at Bernstein
- 04/27/22 Wedbush
- Twitter transaction 'was never ideal' for Tesla investors, says Wedbush
- 04/26/22 Wedbush
- 'Soap opera' now ends with Musk owning Twitter, says Wedbush
- 04/25/22 Gordon Haskett
- Twitter bid more attractive after market selloff, says Gordon Haskett
- 04/25/22 Wedbush
- Twitter bid unlikely to result in major sale of Musk's Tesla stock, says Wedbush
- $2,324.78 /
-1.18 (-0.05%) - 05/02/22 Piper Sandler
- Piper Sandler favors Rivian for exposure to commercial vans
- 05/02/22 Wedbush
- Amazon.com removed from Best Ideas List at Wedbush
- 05/02/22 KeyBanc
- Shopify price target lowered to $650 from $1,000 at KeyBanc
- 05/02/22 Citi
- Amazon overcapacity already previewed in UPS results, says Citi
- 04/13/22 CLSA
- Sony downgraded to Outperform from Buy at CLSA
- 03/08/22 Benchmark
- Take-Two next-gen 'GTA' ports to have lower price point, says Benchmark
- 02/07/22 Morgan Stanley
- Morgan Stanley upgrades TSMC to Overweight, looking beyond current correction
- 01/31/22 Benchmark
- Sony/Bungie deal opens path for Microsoft/Activision close, says Benchmark
- 05/06/22 DZ Bank
- Stellantis upgraded to Buy from Hold at DZ Bank
- 04/26/22 BofA
- Stellantis downgraded to Neutral from Buy at BofA
- 03/23/22 RBC Capital
- RBC cut 2022, 2023 auto forecast on lingering supply chain issues
- 03/15/22 Jefferies
- Stellantis price target lowered to EUR 20 from EUR 25 at Jefferies
- $262.98 /
+10.85 (+4.30%) - 04/07/22 Truist
- Cigna price target raised to $290 from $275 at Truist
- 03/02/22 Mizuho
- Cigna price target raised to $266 from $245 at Mizuho
- 02/07/22 RBC Capital
- Cigna downgraded to Sector Perform from Outperform at RBC Capital
- 02/07/22 Barclays
- Convey Health price target lowered to $12 from $16 at Barclays
- $24.00 /
-3.485 (-12.68%) - 03/21/22 Citi
- Dish price target lowered to $46 from $52 at Citi
- 03/08/22 UBS
- Dish upgraded to Buy from Neutral at UBS
- 02/25/22 Truist
- Dish price target lowered to $32 from $40 at Truist
- 02/25/22 Deutsche Bank
- Dish shares have bottomed, says Deutsche Bank
- $67.14 /
-10.72 (-13.77%) - 05/06/22 Truist
- Cloudflare price target lowered to $140 from $180 at Truist
- 05/06/22 Mizuho
- Cloudflare price target lowered to $90 from $135 at Mizuho
- 05/06/22 Citi
- Cloudflare price target lowered to $95 from $120 at Citi
- 05/02/22 Cowen
- Cloudflare price target lowered to $200 from $250 at Cowen
- 04/21/22 Deutsche Bank
- Goodyear Tire price target lowered to $19 from $30 at Deutsche Bank
- 04/11/22 Exane BNP Paribas
- Goodyear Tire initiated with a Neutral at Exane BNP Paribas
- 02/22/22 Jefferies
- Goodyear Tire downgraded to Hold from Buy at Jefferies
- 02/14/22 Nomura
- Goodyear Tire upgraded to Neutral at Nomura after selloff
- 05/02/22 Benchmark
- Ford price target lowered to $25 from $29 at Benchmark
- 04/28/22 Barclays
- Ford Q1 may bring 'relief rally' in shares, says Barclays
- 04/25/22 JPMorgan
- Ford price target lowered to $21 from $22 at JPMorgan
- 04/21/22 Deutsche Bank
- Ford price target lowered to $17 from $21 at Deutsche Bank
- 03/07/22 BMO Capital
- Funko price target raised to $21 from $18 at BMO Capital
- 03/04/22 DA Davidson
- Funko price target raised to $46 from $34 at DA Davidson
- 08/31/21
- Fly Intel: Top five analyst upgrades
- 08/31/21 Jefferies
- Jefferies upgrades Funko to Buy on confidence in 10%-plus growth
- 05/06/22 Wells Fargo
- eBay price target lowered to $58 from $65 at Wells Fargo
- 05/06/22 Mizuho
- eBay price target lowered to $50 from $60 at Mizuho
- 05/05/22 Baird
- eBay price target lowered to $65 from $80 at Baird
- 05/05/22 Stifel
- eBay price target lowered to $62 from $70 at Stifel
- 03/02/22 Raymond James
- ChemoCentryx could beat consensus 'handily' in Q2, says Raymond James
- 03/02/22 Stifel
- ChemoCentryx's Q4 was positive-launch quarter, says Stifel
- 11/15/21 Raymond James
- InflaRx's ANCA vasculitis data 'solid,' says Raymond James
- 11/10/21 Raymond James
- ChemoCentryx price target raised to $110 from $107 at Raymond James
- 10/13/21 BMO Capital
- Vistra price target raised to $27 from $25 at BMO Capital
- 09/30/21 BofA
- Vistra added to 'US 1 list' at BofA
- 09/29/21 BofA
- Vistra added to US 1 List at BofA
- 07/22/21 Guggenheim
- Guggenheim says 'time is right' to upgrade Vistra to Buy
- 05/06/22 Citi
- GoPro price target lowered to $8 from $9 at Citi
- 03/14/22 Jefferies
- Jefferies 'pleased' to see GoPro taking 'more aggressive competitive posture'
- 02/28/22 Jefferies
- Jefferies starts GoPro at Buy after 'impressive strategic realignment'
- 02/28/22 Jefferies
- GoPro initiated with a Buy at Jefferies
- 03/09/22 Citi
- Endo price target lowered to $6 from $11 at Citi
- 03/03/22 BMO Capital
- Endo price target lowered to $4 from $8 at BMO Capital
- 03/02/22 Barclays
- Barclays downgrades Endo to Underweight on 'difficult path'
- 03/02/22 Barclays
- Endo downgraded to Underweight from Equal Weight at Barclays
- $127.70 /
-24.65 (-16.18%) - 05/06/22 Needham
- Bill.com price target lowered to $200 from $370 at Needham
- 05/06/22 BTIG
- Bill.com price target lowered to $300 from $375 at BTIG
- 05/06/22 Canaccord
- Bill.com price target lowered to $250 from $366 at Canaccord
- 05/06/22 Oppenheimer
- Bill.com price target lowered to $190 from $285 at Oppenheimer
- 05/06/22 Needham
- FuboTV price target lowered to $5 from $15 at Needham
- 05/06/22 Evercore ISI
- FuboTV price target lowered to $7 from $20 at Evercore ISI
- 05/06/22 JPMorgan
- FuboTV downgraded to Underweight from Neutral at JPMorgan
- 05/06/22 Roth Capital
- FuboTV downgraded to Neutral on slowing growth at Roth Capital
VRTX Vertex Pharmaceuticals - $254.63 /
-12.43 (-4.65%) - 05/06/22 Wells Fargo
- Vertex Pharmaceuticals price target raised to $305 from $300 at Wells Fargo
- 05/06/22 Baird
- Vertex Pharmaceuticals downgraded to Neutral at Baird after 21% advance
- 05/06/22 Baird
- Vertex Pharmaceuticals downgraded to Neutral from Outperform at Baird
- 05/06/22 Piper Sandler
- Vertex Pharmaceuticals price target lowered to $242 from $249 at Piper Sandler
MLCO Melco Resorts & Entertainment - 05/06/22 CLSA
- Melco Resorts & Entertainment upgraded to Buy from Outperform at CLSA
- 04/12/22 Citi
- Citi opens '30-day positive Catalyst Watches' on Melco, Galaxy
- 01/18/22 Citi
- Melco Resorts & Entertainment price target raised to $15 from $13.50 at Citi
- 01/10/22 Citi
- Melco Resorts price target lowered to $13.50 from $14.50 at Citi
- 05/06/22 JPMorgan
- JPMorgan downgrades Amarin to sell on headwinds in U.S., Europe
- 05/06/22 JPMorgan
- Amarin downgraded to Underweight from Neutral at JPMorgan
- 05/05/22 H.C. Wainwright
- Amarin downgraded to Neutral from Buy at H.C. Wainwright
- 05/05/22 SVB Leerink
- Amarin downgraded to Market Perform from Outperform at SVB Leerink
- 05/06/22 Canaccord
- Virgin Galactic downgraded to Hold at Canaccord after commercial launch delay
- 05/06/22 Canaccord
- Virgin Galactic downgraded to Hold from Buy at Canaccord
- 02/24/22 Cowen
- Virgin Galactic price target lowered to $15 from $25 at Cowen
- 02/24/22 Susquehanna
- Virgin Galactic price target lowered to $9.00 from $22 at Susquehanna
- 05/05/22
- Zillow Group sees Q2 revenue $903M-$1.03B, consensus $1.81B
- 05/05/22
- Zillow reports Q1 consolidated Adjusted EBITDA of $220M
- 02/10/22
- Notable companies reporting after market close
- 02/10/22
- Zillow reports Q4 consolidated Adjusted EBITDA ($0.4M)
- 05/06/22
- Vistra reports Q1 revenue $3.13B, consensus $3.21B
VRTX Vertex Pharmaceuticals - $254.63 /
-12.43 (-4.65%) - 05/05/22
- Vertex Pharmaceuticals reports Q1 adjusted EPS $3.52, consensus $3.49
- 01/26/22
- Vertex Pharmaceuticals reports Q4 EPS $3.37, consensus $3.29
- $10.02 /
-3.245 (-24.46%) - 05/06/22
- Under Armour sees Q1 EPS 2c-3c, consensus 12c
- 05/06/22
- Under Armour sees FY23 adjusted EPS 63c-68c, consensus 83c
- 05/06/22
- Under Armour reports transition quarter adjusted EPS 1c, consensus 6c
- 05/05/22
- Notable companies reporting before tomorrow's open
- 04/20/22
- Tesla reports Q1 EPS $3.22, consensus $2.26
- 04/20/22
- Notable companies reporting after market close
- 01/26/22
- Tesla reports Q4 non-GAAP EPS $2.54, consensus $2.26
- 01/26/22
- Notable companies reporting after market close
- 05/05/22
- Stellantis reports Q1 revenue EUR 41.5B vs. EUR 37B last year
- 02/23/22
- Stellantis reports FY21 IFRS net revenue EUR 149.42B vs. EUR 47.66B last year
- 05/05/22
- Block reports Q1 adjusted EPS 18c, consensus 21c
- 05/05/22
- Notable companies reporting after market close
- 02/24/22
- Block reports Q4 adjusted EPS 27c, consensus 22c
- 02/24/22
- Notable companies reporting after market close
- 05/05/22
- Virgin Galactic reports Q1 EPS (36c), consensus (32c)
- 02/22/22
- Virgin Galactic reports Q4 EPS (31c), consensus (34c)
- 02/22/22
- Notable companies reporting after market close
- 02/08/22
- Peloton sees FY22 revenue $3.7B-$3.8B, consensus $4.26B
- 02/08/22
- Peloton sees Q3 revenue $950M-$1B, consensus $1.26B
- 02/08/22
- Peloton reports Q2 EPS ($1.39), consensus ($1.20)
- 01/20/22
- Peloton sees Q2 revenue $1.14B, consensus $1.15B
- $67.14 /
-10.72 (-13.77%) - 05/05/22
- Cloudflare backs FY22 adjusted EPS view 3c-4c, consensus 3c
- 05/05/22
- Cloudflare sees Q2 adjusted EPS (1c)-0c, consensus 0c
- 05/05/22
- Cloudflare reports Q1 adjusted EPS 1c, consensus 0c
MLCO Melco Resorts & Entertainment - 05/05/22
- Melco Resorts & Entertainment reports Q1 EPS 38.8c vs 48.8c last year
- 03/01/22
- Melco Resorts & Entertainment reports Q4 EPS (11.2c) vs. (14c) last year
- 11/09/21
- Melco Resorts & Entertainment reports Q3 EPS (48.7c) vs (69.6c) last year
- 04/19/22
- Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60
- 04/19/22
- Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61
- 04/18/22
- Notable companies reporting before tomorrow's open
- 05/06/22
- Icahn Enterprises reports Q1 EPS $1.06 vs. 65c a year ago
- 02/25/22
- Icahn Enterprises reports Q4 EPS ($1.72), one estimate 13c
- 05/06/22
- Goodyear Tire reports Q1 adjusted EPS 37c, consensus 21c
- 02/11/22
- Goodyear Tire reports Q4 adjusted EPS 57c, consensus 32c
- 05/05/22
- GoPro sees Q2 EPS 6c, plus or minus 2c, consensus 15c
- 05/05/22
- GoPro reports Q1 adjusted EPS 9c, consensus 6c
- 02/03/22
- GoPro sees Q1 revenue $210M-$220M, consensus $235.5M
- 05/05/22
- FuboTV reports Q1 EPS (69c), consensus (65c)
- 02/23/22
- FuboTV reports Q4 EPS (57c), consensus (67c)
- 02/23/22
- Notable companies reporting after market close
- 05/05/22
- Funko narrows FY22 EPS view to $1.80-$1.90 from $1.75-$1.91
- 05/05/22
- Funko reports Q1 adjusted EPS 34c, consensus 22c
- 03/03/22
- Funko sees Q1 revenue growth mid-40% range, consensus $205.51M
- 03/03/22
- Funko sees FY22 adjusted EPS $1.75-$1.91, consensus $1.43
- 04/27/22
- Ford reports Q1 adjusted EPS 38c, consensus 37c
- 04/27/22
- Notable companies reporting after market close
- 02/03/22
- Ford reports Q4 adjusted EPS 26c, consensus 45c
- 02/03/22
- Notable companies reporting after market close
- 05/05/22
- Endo sees Q2 adjusted cont ops EPS (17c)-(15c), consensus 48c
- 05/05/22
- Endo reports Q1 adjusted EPS 66c, consensus 44c
- 02/28/22
- Endo sees Q1 EPS 35c-45c, consensus 48c
- 02/28/22
- Endo reports Q4 EPS 84c, consensus 67c
- 05/04/22
- eBay cuts FY22 adj. EPS view to $3.90-$4.10 from $4.20-$4.40
- 05/04/22
- eBay sees Q2 adjusted EPS 87c-91c, consensus $1.01
- 05/04/22
- eBay reports Q1 adjusted EPS $1.05, consensus $1.03
- 05/04/22
- Notable companies reporting after market close
- 05/06/22
- DraftKings raises 2022 revenue view $1.925B-$2.025B from $1.85B-$2B
- 05/06/22
- DraftKings reports Q1 revenue $417M, consensus $412.01M
- 02/18/22
- DraftKings raises 2022 revenue view $1.85B-$2B from $1.7B-$1.9B, consensus $1.9B
- 02/18/22
- DraftKings reports Q4 revenue $473M, consensus $445.3M
- $24.00 /
-3.485 (-12.68%) - 05/06/22
- Dish reports Q1 EPS 68c, consensus 75c
- 02/24/22
- Dish reports Q4 EPS 87c, consensus 87c
- $262.98 /
+10.85 (+4.30%) - 05/06/22
- Cigna raises FY22 adjusted EPS view to at least $22.60 from at least $22.40
- 05/06/22
- Cigna reports Q1 adjusted EPS $6.01, consensus $5.18
- 05/05/22
- ChemoCentryx reports Q1 EPS (55c), consensus (30c)
- 03/01/22
- ChemoCentryx reports Q4 EPS (58c), consensus (58c)
- 11/09/21
- ChemoCentryx reports Q3 EPS (32c), consensus (45c)
- $127.70 /
-24.65 (-16.18%) - 05/05/22
- Bill.com sees FY22 EPS (35c)-(34c), consensus (46c)
- 05/05/22
- Bill.com sees Q4 EPS (14c)-(13c), consensus (15c)
- 05/05/22
- Bill.com reports Q3 EPS (8c), consensus (16c)
- $2,324.78 /
-1.18 (-0.05%) - 05/05/22
- AES Corp.to provide 450 MW of renewable energy to Amazon
- 04/28/22
- Amazon sees Q2 revenue $116B-$121B, consensus $125.55B
- 04/28/22
- Amazon reports Q1 EPS ($7.56) with Rivian expense, consensus $8.36
- 04/28/22
- Notable companies reporting after market close
- 05/04/22
- Amarin reports Q1 adjusted EPS (6c), consensus (2c)
- 03/01/22
- Amarin reports Q4 adjusted EPS 6c, consensus (2c)
- 01/10/22
- Amarin unable to provide 2022 revenue guidance
- 01/10/22
- Amarin reports 2021 revenue $580M, consensus $596.02M
|
Hot Stocks
|
The U.S. Food and Drug… The U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine. "We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community. Our action reflects our updated analysis of the risk of TTS following administration of this vaccine and limits the use of the vaccine to certain individuals," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "Today's action demonstrates the robustness of our safety surveillance systems and our commitment to ensuring that science and data guide our decisions. We've been closely monitoring the Janssen COVID-19 Vaccine and occurrence of TTS following its administration and have used updated information from our safety surveillance systems to revise the EUA. The agency will continue to monitor the safety of the Janssen COVID-19 Vaccine and all other vaccines, and as has been the case throughout the pandemic, will thoroughly evaluate new safety information." Janssen is owned by Johnson & Johnson. Reference Link ShowHide Related Items >><< - 05/02/22
- FDA announces tentative advisory committee meetings on COVID-19 vaccines
- 05/02/22
- Roivant Sciences announces collaborations in targeted protein degradation
- 04/19/22
- Johnson & Johnson announces $77M opioid settlement with Alabama
- 04/19/22
- Johnson & Johnson says continues to invest in R&D at 'competitive levels'
- 04/29/22 Chardan
- Emergent BioSolutions price target lowered to $65 from $75 at Chardan
- 04/20/22 Credit Suisse
- Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
- 04/20/22 Citi
- Johnson & Johnson price target raised to $210 from $203 at Citi
- 04/19/22 Stifel
- J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
- 04/19/22
- Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60
- 04/19/22
- Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61
- 04/18/22
- Notable companies reporting before tomorrow's open
- 05/05/22
- J&J sues SaveOnSP over use of drug cost assistance program, WSJ reports
- 04/27/22
- J&J files suit against HIV-drug counterfeit distributors, WSJ reports
- 03/30/22
- DOJ probes network accused of selling counterfeit HIV drugs, WSJ reports
- 03/27/22
- Pfizer, Moderna face shareholder pressure to broaden vaccine access, WSJ says
- 04/27/22
- What You Missed On Wall Street On Wednesday
- 04/27/22
- What You Missed On Wall Street This Morning
- 04/19/22
- What You Missed On Wall Street On Tuesday
- 04/19/22
- What You Missed On Wall Street This Morning
- 04/19/22
- Unusually active option classes on open April 19th
- 01/25/22
- Unusually active option classes on open January 25th
- 12/17/21
- Unusually active option classes on open December 17th
- 11/12/21
- Unusually active option classes on open November 12th
|
Periodicals
|
Johnson & Johnson… Johnson & Johnson filed a lawsuit on Wednesday accusing SaveOnSP, a drug benefit middleman firm, of contract interference and deceptive trade practices, The Wall Street Journal's Peter Loftus reports. In the lawsuit, J&J said it has paid at least $100M more in copay assistance than it otherwise would have as a result of the services provided by the firm. J&J is seeking damages and a court order that SaveOnSP stop its program. Reference Link ShowHide Related Items >><< - 05/02/22
- FDA announces tentative advisory committee meetings on COVID-19 vaccines
- 05/02/22
- Roivant Sciences announces collaborations in targeted protein degradation
- 04/19/22
- Johnson & Johnson announces $77M opioid settlement with Alabama
- 04/19/22
- Johnson & Johnson says continues to invest in R&D at 'competitive levels'
- 04/29/22 Chardan
- Emergent BioSolutions price target lowered to $65 from $75 at Chardan
- 04/20/22 Credit Suisse
- Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
- 04/20/22 Citi
- Johnson & Johnson price target raised to $210 from $203 at Citi
- 04/19/22 Stifel
- J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
- 04/19/22
- Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60
- 04/19/22
- Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61
- 04/18/22
- Notable companies reporting before tomorrow's open
- 04/27/22
- J&J files suit against HIV-drug counterfeit distributors, WSJ reports
- 03/30/22
- DOJ probes network accused of selling counterfeit HIV drugs, WSJ reports
- 03/27/22
- Pfizer, Moderna face shareholder pressure to broaden vaccine access, WSJ says
- 03/23/22
- Biden administration eyes new COVID booster shot recommendation, Politico says
- 04/27/22
- What You Missed On Wall Street On Wednesday
- 04/27/22
- What You Missed On Wall Street This Morning
- 04/19/22
- What You Missed On Wall Street On Tuesday
- 04/19/22
- What You Missed On Wall Street This Morning
- 04/19/22
- Unusually active option classes on open April 19th
- 01/25/22
- Unusually active option classes on open January 25th
- 12/17/21
- Unusually active option classes on open December 17th
- 11/12/21
- Unusually active option classes on open November 12th
|
Conference/Events
|
ARVO 2022 to be held in… ARVO 2022 to be held in Denver, CO on May 1-4. ShowHide Related Items >><< - 04/28/22
- Allogene Therapeutics appoints Lundeen as Chief People Officer
- 04/19/22
- Unity Biotechnology doses first patient in ENVISION study of UBX1325
- 04/12/22
- Unity Biotechnology completes enrollment in BEHOLD study
- 03/15/22
- Unity Biotechnology expects cash to fund operations into 1Q23
- 05/02/22
- Stoke Therapeutics presents new in-vivo data for STK-002
- 12/03/21
- Stoke Therapeutics presents data from Phase 1/2a MONARCH study of STK-001
- 04/29/22
- Genentech announces new three-year data from FIREFISH study
- 04/25/22
- Roche sees FY22 sales stable or up in low single digits
- 04/25/22
- Roche confirms outlook for 2022
- 04/22/22
- Roche reports CHMP recommends approval of Tecentriq as adjuvant NSCLC treatment
- 02/09/22
- Regenxbio reporting 'additional positive interim data' from MPS II trial
- 01/06/22
- Regenxbio announces FDA clearance of IND for clinical trial of RGX-202
- 11/22/21
- Regenxbio announces FDA Orphan Drug Designation for RGX-202
- 11/12/21
- Regenxbio reports additional positive interim data from trials of RGX-314
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/19/22
- Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash
- 04/13/22
- ProQR Therapeutics announces additional sepofarsen Illuminate trial analyses
- 04/13/22
- ProQR Therapeutics expects cash to fund operations into 2025
- 04/13/22
- ProQR Therapeutics to reduce workforce by 30%, CSO Naveed Shams to depart
- 04/13/22
- ProQR Therapeutics suspends development of QR-1123, QR-504a
LCTX Lineage Cell Therapeutics - 04/25/22
- Lineage Cell Therapeutics announces new cell therapy development program
- 04/20/22
- Enochian Biosciences appoints Binette as EVP for Research, Development
- 04/13/22
- Lineage Cell announces Cancer Research UK completes enrollment for VAC2 trial
- 12/20/21
- Lineage Cell Therapeutics enters license agreement with Roche, Genentech
- 02/23/22
- Kodiak Sciences announces KSI-301 trial did not meet primary efficacy endpoint
- 02/03/22
- Kodiak Sciences completes enrollment in GLEAM, GLIMMER trials
- 12/16/21
- Kodiak Sciences completes enrollment in BEACON trial
KALA Kala Pharmaceuticals - 05/03/22
- Kala announces new commercial, Medicare coverage for EYSUVIS
- 05/01/22
- Kala Pharmaceuticals to present clinical data for KPI-012 at ARVO Annual Meeting
- 03/29/22
- Kala Pharmaceuticals expects cash to fund operations into Q2 of 2023
- 03/08/22
- Kala Pharmaceuticals announces EYSUVIS now covered by UnitedHealthcare, Cigna
- 05/02/22
- FDA announces tentative advisory committee meetings on COVID-19 vaccines
- 05/02/22
- Roivant Sciences announces collaborations in targeted protein degradation
- 04/19/22
- Johnson & Johnson announces $77M opioid settlement with Alabama
- 04/19/22
- Johnson & Johnson says continues to invest in R&D at 'competitive levels'
HZNP Horizon Therapeutics - 05/03/22
- Horizon Therapeutics announces dazodalibep trial meets primary endpoint
- 05/02/22
- Roivant Sciences appoints Srini Ramanathan as CDO
- 05/02/22
- Horizon Therapeutics announces EC approval of Uplinza
- 04/11/22
- Eton Pharmaceuticals CFO Wilson Troutman to retire, James Gruber to succeed
- 04/26/22
- Editas Medicine receives FDA Rare Pediatric Disease designation for EDIT-301
- 04/14/22
- Editas Medicine appoints Gilmore O'Neill as CEO
- 04/11/22
- Editas Medicine announces dosing of first pediatric patient in BRILLIANCE trial
- 04/08/22
- Editas Medicine reports engineered iNK cell preclinical data
- 04/26/22
- Cathie Wood's ARK Investment bought 1.3M shares of Ginkgo Bioworks today
- 04/25/22
- Cathie Wood's ARK Investment bought 232.6K shares of Ginkgo Bioworks today
- 04/20/22
- Cathie Wood's ARK Investment bought 881K shares of Ginkgo Bioworks today
- 02/15/22
- FDA grants Celularity fast track designation for CYNK-101
- 02/14/22
- Celularity's treatment of gastric junction cancer gets FDA orphan designation
- 01/18/22
- Celularity receives Fast Track Designation for CYNK-101
- 12/27/21
- Celularity receives Fast Track Designation for CYNK-001
- 03/31/22
- Celanese sees EPS accretion from KEP restructuring 15-20c over three years
- 02/18/22
- DuPont to divest majority of mobility and materials segment to Celanese for $11B
- 02/18/22
- Celanese to acquire majority of DuPont M&M business for $11B in cash
- 02/07/22
- Linde expands existing agreement with Celanese
- 03/17/22
- BioMarin's hemophilia A candidate shows efficacy in published article
- 02/24/22
- BioMarin trading resumes
- 02/24/22
- BioMarin trading halted, volatility trading pause
- 02/17/22
- BioMarin provides updates on progress in gene therapy programs
- 04/22/22
- Ginkgo Bioworks announces partnership with Bayer
- 04/12/22
- ALX Oncology appoints Canamasas to board of directors
- 04/11/22
- 22nd Century appoints Calvin Treat as CSO
- 03/24/22
- Bayer's Monsanto settles with Ohio Attorney General for $80M
- 03/22/22
- Applied Genetic announces pricing of public offering of common stock
- 02/14/22
- Applied Genetic expects cash to fund operations into 2023
- 02/08/22
- Applied Genetic announces interim data from studies of AGTC-401, AGTC-402
- 01/11/22
- Applied Genetic exceeds enrollment target in SKYLINE trial of AGTC-501
AERI Aerie Pharmaceuticals - 03/21/22
- Ocugen names Jessica Crespo as Chief Accounting Officer
- 03/18/22
- Aerie Pharmaceuticals announces Peter Lang as CFO
- 02/24/22
- Aerie Pharmaceuticals sees FY Glaucoma franchise net product revenues up 16%-25%
- 02/24/22
- Aerie Pharmaceuticals names Gary Sternberg as Chief Medical Officer
ADVM Adverum Biotechnologies - 05/01/22
- Adverum presents additional efficacy, safety data from OPTIC trial of ADVM-022
- 04/06/22
- Adverum proceeds with IND amendment for wet AMD trial after FDA Type C feedback
- 03/29/22
- Nkarta Adverum appoints Thedinga to board of directors
- 02/07/22
- Adverum Biotechnologies appoints Richard Beckman as CMO
- 04/29/22
- Abeona Therapeutics announces pricing of $25M private placement
- 03/14/22
- Abeona Therapeutics reaches target enrollment in Phase 3 VIITAL study of EB-101
- 03/09/22
- Abeona Therapeutics CFO Edward Carr resigns
- 12/22/21
- Abeona issues letter to shareholders on 2022 anticipated milestones
- 04/29/22
- AbbVie's RINVOQ approved by FDA for treatment of active AS
- 04/29/22
- AbbVie says no plans to cut R&D investments in 2023
- 04/29/22
- AbbVie says cystic fibrosis combination drug missed study goal
- 04/29/22
- AbbVie says confident in long-term fundamentals of business
- 05/03/22 Morgan Stanley
- Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
- 05/02/22 Morgan Stanley
- AbbVie's recent weakness a buying opportunity, says Morgan Stanley
- 05/02/22 Wells Fargo
- AbbVie price target raised to $200 from $165 at Wells Fargo
- 05/02/22 Cowen
- Genmab initiated with a Market Perform at Cowen
- 11/30/21 SVB Leerink
- Abeona Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
- 11/29/21 H.C. Wainwright
- Abeona Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
- 07/19/21 H.C. Wainwright
- Abeona Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
ADVM Adverum Biotechnologies - 03/29/22 Chardan
- Adverum Biotechnologies transferred with Neutral at Chardan
- 07/23/21
- Fly Intel: Top five analyst downgrades
- 07/23/21 Goldman Sachs
- Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
- 07/23/21 SVB Leerink
- Adverum Biotechnologies price target lowered to $2 from $5
AERI Aerie Pharmaceuticals - 02/28/22 Citi
- Aerie Pharmaceuticals price target lowered to $13 from $23 at Citi
- 02/25/22 Cowen
- Aerie Pharmaceuticals price target lowered to $25 from $30 at Cowen
- 03/29/22 Chardan
- Applied Genetic transferred with Buy rating at Chardan
- 02/14/22 Stifel
- Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
- 09/24/21 Roth Capital
- Applied Genetic near-term readouts 'major catalysts,' says Roth Capital
- 07/09/21 Chardan
- Applied Genetic coverage transferred at Chardan
- 04/25/22 Morgan Stanley
- Bayer price target raised to EUR 83 from EUR 77 at Morgan Stanley
- 04/05/22 Barclays
- Bayer upgraded to Overweight from Equal Weight at Barclays
- 03/15/22 Barclays
- Bayer price target raised to EUR 60 from EUR 55 at Barclays
- 03/14/22 Jefferies
- Bayer initiated with a Buy at Jefferies
- 04/28/22 Wedbush
- BioMarin price target lowered to $147 from $155 at Wedbush
- 04/25/22 Morgan Stanley
- BioMarin upgraded to Overweight from Equal Weight at Morgan Stanley
- 02/24/22 Piper Sandler
- BioMarin price target raised to $125 from $121 at Piper Sandler
- 01/10/22 JPMorgan
- JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
- 04/13/22 Fermium Research
- DuPont price target lowered to $78 from $87 at Fermium Research
- 04/08/22 JPMorgan
- Celanese added to Analyst Focus List at JPMorgan
- 02/22/22 Deutsche Bank
- Celanese likely to split-up in 2024 or 2025, says Deutsche Bank
- 02/22/22 Piper Sandler
- Celanese downgraded to Underweight from Neutral at Piper Sandler
- 04/06/22 Truist
- Celularity downgraded to Hold from Buy at Truist
- 04/01/22 Oppenheimer
- Celularity price target raised to $10 from $9 at Oppenheimer
- 01/27/22 Oppenheimer
- Celularity initiated with an Outperform at Oppenheimer
- 11/24/21 Morgan Stanley
- Celularity initiated with an Equal Weight at Morgan Stanley
- 03/31/22 BTIG
- Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
- 03/29/22 Cowen
- Ginkgo Bioworks weakness a buying opportunity, says Cowen
- 03/02/22 Cowen
- Ginkgo Bioworks initiated with an Outperform at Cowen
- 02/23/22 Goldman Sachs
- Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
- 04/18/22 Baird
- Editas Medicine price target lowered to $33 from $44 at Baird
- 02/25/22 SVB Leerink
- Editas Medicine price target lowered to $27 from $41 at SVB Leerink
- 02/25/22 Barclays
- Editas Medicine price target lowered to $18 from $39 at Barclays
- 02/25/22 Chardan
- Editas Medicine price target lowered to $60 from $75 at Chardan
HZNP Horizon Therapeutics - 03/14/22 Oppenheimer
- Horizon Therapeutics initiated with an Outperform at Oppenheimer
- 01/26/22 Piper Sandler
- Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
- 01/18/22 JPMorgan
- Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
- 12/08/21
- Fly Intel: Top five analyst initiations
- 04/29/22 Chardan
- Emergent BioSolutions price target lowered to $65 from $75 at Chardan
- 04/20/22 Credit Suisse
- Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
- 04/20/22 Citi
- Johnson & Johnson price target raised to $210 from $203 at Citi
- 04/19/22 Stifel
- J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
KALA Kala Pharmaceuticals - 03/30/22 Northland
- Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
- 03/30/22 H.C. Wainwright
- Kala Pharmaceuticals price target lowered to $6 from $9 at H.C. Wainwright
- 03/30/22 JPMorgan
- Kala Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
- 12/15/21 Wedbush
- Kala Pharmaceuticals assumed with an Outperform, $6 target at Wedbush
- 04/13/22 Truist
- Kodiak Sciences price target lowered to $10 from $35 at Truist
- 03/29/22 Chardan
- Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
- 02/28/22 Roth Capital
- Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
- 02/24/22 Truist
- Kodiak Sciences price target lowered to $35 from $147 at Truist
LCTX Lineage Cell Therapeutics - 04/25/22 H.C. Wainwright
- Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
- 08/19/21 Noble Capital
- Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
- 04/19/22 Cantor Fitzgerald
- ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
- 04/14/22 Chardan
- ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
- 03/15/22 Citi
- ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
- 02/14/22 Citi
- ProQR Therapeutics downgraded to Neutral from Buy at Citi
- 04/20/22 Cowen
- Regeneron price target raised to $645 from $640 at Cowen
- 04/20/22 BTIG
- Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
- 04/19/22 Baird
- Decibel could be next target for Regeneron, says Baird
- 04/12/22 Barclays
- Regeneron price target raised to $745 from $700 at Barclays
- 03/29/22 Chardan
- Regenxbio price target lowered to $76 from $90 at Chardan
- 02/10/22 SVB Leerink
- Regenxbio price target lowered to $29 from $35 at SVB Leerink
- 12/15/21
- Fly Intel: Top five analyst initiations
- 12/15/21 Wedbush
- Wedbush initiates Regenxbio with a Neutral rating, price target of $29
- 05/03/22 Piper Sandler
- Piper keeps Overweight rating on Ionis after Biogen's Spinraza beat
- 04/26/22 Stifel
- Arvinas price target lowered to $85 from $93 at Stifel
- 04/19/22 UBS
- Roche downgraded to Sell from Neutral at UBS
- 01/31/22 Jefferies
- Stoke Therapeutics initiated with a Buy at Jefferies
- 12/03/21
- Fly Intel: Top five analyst initiations
- 12/03/21 BofA
- Stoke Therapeutics initiated with a Buy at BofA
- 12/03/21 BofA
- Stoke Therapeutics initiated with a Buy at BofA
- 01/04/22 Roth Capital
- Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
- 01/04/22 Roth Capital
- Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
- 12/15/21 Wedbush
- Wedbush bullish on Unity Biotechnology, initiates with an Outperform
- 12/15/21 Wedbush
- Unity Biotechnology assumed with an Outperform at Wedbush
- 03/15/22
- Unity Biotechnology reports Q4 EPS (18), consensus (38c)
- 11/10/21
- Unity Biotechnology reports Q3 EPS (30c), consensus (37c)
- 03/10/22
- Stoke Therapeutics reports Q4 EPS (66c), consensus (62c)
- 11/08/21
- Stoke Therapeutics reports Q3 EPS (61c), consensus (59c)
- 04/25/22
- Roche reports Q1 group sales CHF 16.445B vs. CHF 14.93B last year
- 02/03/22
- Roche sees FY22 core earnings growing in low- to mid-single digit range
- 02/03/22
- Roche reports 2021 core EPS CHF 19.81 vs CHF 19.16
- 03/01/22
- Regenxbio reports Q4 EPS $6.67, consensus $4.71
- 02/04/22
- Regeneron reports Q4 EPS $23.72, consensus $18.02
- 02/03/22
- Notable companies reporting before tomorrow's open
- 11/04/21
- Regeneron reports Q3 EPS $15.37, consensus $9.56
- 02/24/22
- ProQR Therapeutics reports Q4 EPS (EUR0.26) vs. (EUR0.26) last year
- 11/04/21
- ProQR Therapeutics reports Q3 EPS (EUR0.22) vs. (EUR0.26) last year
LCTX Lineage Cell Therapeutics - 03/10/22
- Lineage Cell Therapeutics reports Q4 EPS (17c), consensus (5c)
- 11/10/21
- Lineage Cell Therapeutics reports Q3 EPS (5c), consensus (5c)
- 03/01/22
- Kodiak Sciences reports Q4 EPS ($1.79), consensus ($1.36)
- 11/09/21
- Kodiak Sciences reports Q3 EPS ($1.30), consensus ($1.16)
KALA Kala Pharmaceuticals - 03/29/22
- Kala Pharmaceuticals reports Q4 EPS (68c), consensus (41c)
- 11/15/21
- Kala Pharmaceuticals reports Q3 EPS (43c), consensus (43c)
- 04/19/22
- Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60
- 04/19/22
- Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61
- 04/18/22
- Notable companies reporting before tomorrow's open
HZNP Horizon Therapeutics - 03/01/22
- Horizon Therapeutics sees FY22 revenue $3.9B-$4B, consensus $3.91B
- 03/01/22
- Horizon Therapeutics reports Q4 EPS $1.41, consensus $1.34
- 02/24/22
- Editas Medicine reports Q4 EPS (61c), consensus (72c)
- 11/08/21
- Editas Medicine reports Q3 EPS (57c), consensus (82c)
- 03/28/22
- Ginkgo Bioworks sees FY22 revenue $325M-$340M, consensus $305.75M
- 03/28/22
- Ginkgo Bioworks reports Q4 EPS ($1.10), consensus (4c)
- 01/12/22
- Ginkgo Bioworks sees 2021 revenue above guidance
- 11/15/21
- Ginkgo Bioworks reports Q3 EPS (8c), two estimates (3c)
- 11/12/21
- Celularity reports Q3 EPS 40c, consensus (34c)
- 04/28/22
- Celanese sees FY22 adjusted EPS approaching FY21 adjusted EPS
- 04/28/22
- Celanese reports Q1 adjusted EPS $5.54, consensus $4.52
- 01/27/22
- Celanese sees FY22 EPS 'at least' $15.00, consensus $15.85
- 01/27/22
- Celanese sees Q1 EPS $4.30-$4.60, consensus $4.19
- 04/27/22
- BioMarin backs FY22 revenue view $2.05B-$2.15B, consensus $2.1B
- 04/27/22
- BioMarin reports Q1 GAAP EPS 63c, consensus 17c
- 02/23/22
- BioMarin sees FY22 revenue $2.05B-$2.15B, consensus $2.14B
- 02/23/22
- BioMarin reports Q4 GAAP EPS (32c), consensus (32c)
- 03/01/22
- Bayer sees 2022 group sales of EUR 47B
- 03/01/22
- Bayer reports Q4 core EPS EUR 1.26 vs. EUR 1.32 last year
- 11/09/21
- Bayer reports Q3 core EPS EUR 1.05 vs. EUR 0.81 last year
- 02/14/22
- Applied Genetic reports Q2 EPS (45c), consensus (38c)
- 11/09/21
- Applied Genetic sees cash, cash equivalents funding operations into 2023
- 11/09/21
- Applied Genetic reports Q1 EPS (40c), consensus (35c)
AERI Aerie Pharmaceuticals - 02/24/22
- Aerie Pharmaceuticals reports Q4 EPS $1.09, consensus (67c)
- 11/04/21
- Aerie Pharmaceuticals reports Q3 adjusted EPS (72c), consensus (62c)
ADVM Adverum Biotechnologies - 03/29/22
- Adverum Biotechnologies reports Q4 EPS (35c), consensus (34c)
- 11/04/21
- Adverum Biotechnologies reports Q3 EPS (39c), consensus (37c)
- 03/31/22
- Abeona Therapeutics reports Q4 EPS (45c), consensus (15c)
- 11/15/21
- Abeona Therapeutics reports Q3 EPS (7c), consensus (16c)
- 04/29/22
- AbbVie sees FY22 revenue $59.4B, consensus $60.22B
- 04/29/22
- AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50
- 04/29/22
- AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20
- 04/29/22
- AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14
|